Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Johnson & Johnson Q1 Earnings: Drug‑Pricing Deals, Tariff Threats & Cutting‑Edge Therapies

Johnson & Johnson’s Q1 earnings reveal strong profitability and a growing pipeline of gene‑editing, bispecific antibody and targeted kinase therapies, while navigating U.S. drug‑pricing and tariff policy.

Dr. Michael Chen

03/04/2026, 22:15

4 minutes to read

How Novo Nordisk Is Winning the GLP‑1 Battle with Subscription Models, Digital‑Health Partnerships, and Smart Pricing

How Novo Nordisk is using subscription pricing, digital‑health partnerships, NICE approvals, and price cuts to protect its GLP‑1 market leadership amid patent erosion and rising competition.

Dr. Michael Chen

01/04/2026, 20:00

5 minutes to read

Pfizer’s 2026 Update: Executive Ownership, Fc‑Fusion Biologics, & Legal Cost Controls

Pfizer’s latest corporate moves: phantom‑stock conversion aligns executive ownership, Fc‑fusion biologics lead in trials, and legal tech cuts litigation costs.

Dr. Michael Chen

31/03/2026, 16:48

3 minutes to read

Biogen’s Litifilimab Shines in Phase‑2 CLE Trial, Achieving Key Efficacy Milestones

Biogen’s litifilimab shows significant Phase‑2 success in cutaneous lupus, offering a targeted IFN‑α blocker that could reshape autoimmune therapy.

Dr. Michael Chen

31/03/2026, 04:54

3 minutes to read

Shanghai Fosun Pharma’s Quiet Position: Why Investors Must Watch Its Pipeline and Partnerships

Explore why Shanghai Fosun Pharmaceutical’s quiet market stance matters, the hidden pipeline insights, and how investors and partners can spot its next breakthrough in China’s innovation‑drug scene.

Dr. Michael Chen

29/03/2026, 16:04

3 minutes to read

Pfizer Shares Surge on Analyst Upgrades and Promising Phase‑II Breast‑Cancer Data

Pfizer shares surge after analyst upgrade and promising phase‑II breast‑cancer data for PF‑Lym‑210, highlighting strong pipeline and solid earnings growth.

Dr. Michael Chen

27/03/2026, 14:28

3 minutes to read

AbbVie Beats Q4 Expectations, Boosts 2026 Outlook, & Launches Promising Obesity Drug

AbbVie’s Q4 earnings beat forecasts, raising 2026 profit outlook while its Phase‑1 obesity drug ABBV‑295 shows strong appetite‑reduction safety, signaling a new growth avenue and investor confidence.

Dr. Michael Chen

26/03/2026, 19:05

4 minutes to read

How Bayer AG’s Share Sale, Labor Deals, and New Biotech Projects Drive Growth and Stability

Explore Bayer AG’s strategic realignment: share sale, labor cost stability, and breakthrough biologics like BAY‑001 for metastatic melanoma and BAY‑002 for diabetes, plus a crop‑protection partnership, all aimed at boosting financial health and scie…

Dr. Michael Chen

26/03/2026, 16:36

3 minutes to read

Eisai Highlights Lecanemab’s 2025 Success & 2026 Persistence Data, Boosting Long‑Term Alzheimer’s Therapy Outlook

Explore Eisai’s 2025 results and 2026 outlook for lecanemab, highlighting long‑term patient retention, safety, and FDA/EMA regulatory prospects in Alzheimer’s therapy.

Dr. Michael Chen

24/03/2026, 21:36

3 minutes to read

Shanghai Fosun Pharma Forecasts Stable Q4 Earnings, Highlights Oncology Pipeline

Shanghai Fosun Pharmaceutical Q4 2025 outlook: stable EPS, slight revenue dip, and a robust pipeline featuring a KRAS G12C oncology lead and a GLP‑1 diabetes candidate, all under strong cost‑control strategy.

Dr. Michael Chen

24/03/2026, 18:38

3 minutes to read

Older articles